𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The relative toxicity of disease-modifying antirheumatic drugs

✍ Scribed by James F. Fries; Catherine A. Williams; Dena Ramey; Daniel A. Bloch

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
819 KB
Volume
36
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prior authorization for biologic disease
Prior authorization for biologic disease-modifying antirheumatic drugs: A description of US medicaid programs
✍ Fischer, Michael A. ;Polinski, Jennifer M. ;Servi, Amber D. ;Agnew-Blais, Jessic πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

## Abstract ## Objective To evaluate state Medicaid prior authorization programs for biologic disease‐modifying antirheumatic drugs (DMARDs). ## Methods We obtained biologic DMARD prior authorization policy information from state Medicaid programs. Using aggregate Medicaid drug spending data, we

Interleukin-6 receptor inhibition with t
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 2 views